Immunotherapy after surgery for colon cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests whether an immunotherapy drug called tislelizumab can help prevent colon cancer from coming back after surgery. It is for people with a specific genetic feature (dMMR) in their tumor, which may make the treatment more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are in good enough health to carry out daily activities (performance status 0 or 1).
- You have stage II or stage III colon cancer that has been completely removed by surgery.
- Your tumor has a specific genetic feature called dMMR (deficient mismatch repair), which means your body might respond well to immunotherapy.
- You have not had prior chemotherapy, radiation, or other treatments for this colon cancer, except possibly one round of standard chemo.
- You do not have certain health issues like active autoimmune disease, serious heart problems, or a history of lung inflammation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving the immunotherapy drug pembrolizumab before surgery can shrink or eliminate colon tumors in people with dMMR/MSI-high cancer, possibly allowing some to avoid surgery. It is for patients whose cancer has not spread.
This trial tests whether a drug called an immune checkpoint inhibitor (PD-1 blocker) can help lower the risk of cancer returning after surgery. It is for people with a specific type of colorectal cancer (dMMR or MSI-H) that had certain high-risk features.
This trial tests a new immunotherapy drug (tislelizumab) given before surgery for people with stage II or III colorectal cancer that has a specific DNA repair problem (dMMR/MSI-High). The drug aims to shrink the tumor and improve treatment outcomes.
This trial tests whether giving an immunotherapy drug (tislelizumab) together with chemotherapy before and after surgery can improve outcomes for people with a specific type of colorectal cancer (MSI-high). The goal is to see if this treatment helps shrink the tumor and reduces the risk of cancer coming back.
This trial tests whether giving an immunotherapy drug called toripalimab after surgery can lower the chance of colon cancer coming back. It is for people whose tumors have a specific genetic feature called mismatch repair deficiency (dMMR) and who have had their cancer completely removed.
This trial tests whether giving chemotherapy followed by an immunotherapy drug (tislelizumab) after surgery can help prevent your cancer from coming back. It's especially for people whose tumors have certain genetic features that may make them more responsive to immunotherapy.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.